2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. MMP
  5. MMP-9 Isoform

MMP-9

MMP-9 (matrix metalloproteinase-9), also known as gelatinase B, is a zinc-dependent extracellular endopeptidase that mediates extracellular matrix remodeling through proteolytic cleavage of gelatin, type IV collagen, laminin, elastin, and additional matrix-associated substrates, thereby regulating tissue turnover, cell migration, and microenvironmental remodeling[1][2]. Mechanistically, MMP-9 is synthesized as an inactive proenzyme and becomes activated through proteolytic removal of its prodomain, enabling participation in inflammatory signaling, leukocyte trafficking, angiogenesis, and tissue repair processes[1][3]. MMP-9 also modulates biological activity of cytokines, chemokines, growth factors, and cell-surface signaling molecules, linking extracellular matrix degradation with immune and vascular responses[3][4]. In disease settings, dysregulated or persistent MMP-9 expression is associated with cancer progression, invasion, metastasis, vascular remodeling, neuroinflammatory disorders, and blood-brain barrier disruption, making MMP-9 a widely studied pathogenic mediator and biomarker candidate[3][5][6]. Compared with the closely related gelatinase MMP-2, MMP-9 displays distinct substrate preferences, inducible expression in inflammatory conditions, predominant storage in neutrophils, and primary inhibition by TIMP-1, whereas MMP-2 is generally constitutively expressed and preferentially regulated by TIMP-2[4]. Structural differences, including a unique loop region and distinct regulatory mechanisms, further support functional separation between the two gelatinases in physiological and pathological remodeling[2][4]. For experimental applications, MMP-9-selective inhibitors and neutralizing antibodies are widely used to investigate extracellular matrix remodeling, angiogenesis, inflammatory responses, and tumor progression, although achieving high selectivity remains a major challenge because of structural homology within the matrix metalloproteinase family[5][7].

Cat. No. Product Name Effect Purity
  • HY-15768
    Ilomastat
    		Inhibitor 99.14%
    Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (MMP) inhibitor, inhibits MMPs (IC50s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a Ki of 0.4 nM for human skin fibroblast collagenase (MMP-1).
  • HY-N0431
    Astragaloside IV
    		Inhibitor 99.93%
    Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
  • HY-N0318
    Salvianolic acid A
    		99.72%
    Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.
  • HY-12354
    SB-3CT
    		Inhibitor 99.84%
    SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity.
  • HY-154919
    DC-Y13-27
    		Inhibitor 99.52%
    DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer.
  • HY-181654
    Snail IN-1
    		Inhibitor 98.27%
    Snail IN-1 is an orally active Snail inhibitor with a Ka of 0.36 μM.Snail IN-1 disrupts Snail-CBP interaction, accelerates Snail protein degradation, reduces Snail acetylation, increases Snail polyubiquitination, and selectively downregulates Snail protein without altering other EMT transcription factors.Snail IN-1 reduces atherosclerotic plaque burden, modulates inflammation and plaque stability factors, downregulates CCL5, CXCL10, MMP2, and MMP9, and upregulates α-smooth muscle actin.Snail IN-1 exerts anti-inflammatory and plaque-stabilizing properties.Snail IN-1 can be used for the research of atherosclerosis.
  • HY-177990
    STAT3-IN-52
    		Inhibitor
    STAT3-IN-52 (Compound 9) is a selective and orally active signal transducer and activator of transcription 3 (STAT3) inhibitor. STAT3-IN-52 binds to the pY705 site of STAT3 (Ki = 440 nM), blocking the phosphorylation and dimerization of STAT3. STAT3-IN-52 shows strong cytotoxicity against various cancer cells, such as breast cancer MDA-MB-231 (IC50 = 0.7 μM), medulloblastoma UW426, pancreatic cancer BKPC3 cells. STAT3-IN-52 can induce cell apoptosis, inhibit the STAT3 nuclear transport and DNA binding activity and downregulate the expression of the STAT3 target gene MMP9. STAT3-IN-52 can be used for research related to STAT3 abnormal activation in cancer.
  • HY-N16746
    Nordentatin
    		Inhibitor
    Nordentatin is a selective inhibitor targeting GSK-3 with anticancer activity. Nordentatin can inhibit the phosphorylation of GSK-3, downregulate the anti-apoptotic protein Mcl-1 and activate caspase-3 to induce apoptosis (apoptosis). Nordentatin also inhibits the expression of migration-related protein MMP-9 and exerts anti-proliferation and anti-migration activities. Nordentatin is used in research into cancers such as neuroblastoma.
  • HY-W016562
    Hippuric acid
    		Inhibitor 99.98%
    Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research. .
  • HY-12723
    Apomorphine
    		Inhibitor 99.48%
    Apomorphine ((-)-Apomorphine) is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction.
  • HY-135232
    MMP-9-IN-1
    		Inhibitor 99.82%
    MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.
  • HY-110397
    KP-457
    		Inhibitor 99.18%
    KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC50s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively.
  • HY-103444
    ARP-100
    		Inhibitor ≥99.0%
    ARP-100 is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with S1＇ pocket of MMP-2 and shows anti-invasive properties in an in vitro model of invasion on matrigel. ARP-100 shows the less inhibitory activity towards MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM), and MMP-9 (0.2 μM).
  • HY-N1454
    Apigenin-7-glucuronide
    		Inhibitor 99.74%
    Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.
  • HY-P2036A
    FSL-1 TFA
    		Agonist 99.81%
    FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells.
  • HY-N1463
    Luteolin 7-O-glucuronide
    		Inhibitor 99.98%
    Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively.
  • HY-P4373A
    Hepcidin-1 (mouse) TFA
    		Inducer 98.86%
    Hepcidin-1 (mouse) TFA is an endogenous peptide hormone involved in the regulation of iron homeostasis. Hepcidin-1 (mouse) TFA upregulates mRNA levels of TRAP, cathepsin K, and MMP-9 and increases TRAP-5b protein secretion. Hepcidin-1 (mouse) TFA downregulates the level of FPN1 protein and increases intracellular iron. Hepcidin-1 (mouse) TFA facilitates osteoclast differentiation.
  • HY-B1260
    Cetrimonium bromide
    		98.0%
    Cetrimonium bromide (CTAB), a quaternary ammonium, is an orally active cationic surfaetant. Cetrimonium bromide has toxicity and anticancer effect. Cetrimonium bromide inhibits cell migration and invasion through modulating the canonical and non-canonical TGF-β signaling pathways. Cetrimonium bromide can be used for DNA extraction.
  • HY-N0532
    Morroniside
    		Inhibitor 99.94%
    Morroniside has neuroprotective effect by inhibiting neuron apoptosis and MMP2/9 expression.
  • HY-N7700A
    Guluronic acid sodium
    		Inhibitor 98.0%
    Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases.
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity